



Form PTO-1449 Modified		Docket No. CELL-0308/PA535-USw01	Application No. 10/562,769
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Sam Philip Heywood, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 27, 2006	Group Not Yet Assigned
		Confirmation No. 7843	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	1	Begg, et al., "Mass spectrometry detection and reduction of disulfide adducts between reducing agents and recombinant proteins with highly reactive cysteines," <i>J. of Biomolecular Techniques</i> , 1999 , <i>10</i> , 17-20	
	2	Bird, R.E., et al., "Single-chain antigen-binding proteins," <i>Science</i> , 1988 , <i>242</i> , 423	
	3	Burns, J., et al., "Selective reduction of disulfides by tris(2-carboxyethyl)phosphine," <i>J. Org. Chem.</i> , 1991 , <i>56</i> , 2648-2650	
	4	Chapman, A.P., et al., "Therapeutic antibody fragments with prolonged in vivo half-lives," <i>Nature Biotechnology</i> , 1999 , <i>17</i> , 780-783	
	5	Chapman, A.P., et al., "PEGylated antibodies and antibody fragments for improved therapy: a review," <i>Advanced Drug Delivery Reviews</i> , 2002 , <i>54</i> , 531-545	
	6	Dubowchik, G.M., et al., "Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs," <i>Pharmacology and Therapeutics</i> , 1999 , <i>83</i> , 67-123	
	7	Ellison, D., et al., "Photoreduction of monoclonal antibodies for conjugation and fragmentation," <i>Biotechniques</i> , 2000 , <i>28</i> (2), 324-326	
	8	Getz, E.B., et al., "A comparison between the sulphydryl reductants tris(2-carboxyethyl)phosphine and dithiothreitol for use in protein biochemistry," <i>Analytical Biochemistry</i> , 1999 , <i>273</i> , 73-80	
	9	Han, J.C., et al., "A procedure for quantitative determination of Tris(2-carboxyethyl)phosphine, an odorless reducing agent more stable and effective than dithiothreitol," <i>Analytical Biochemistry</i> , 1994 , <i>220</i> , 5-10	
	10	Hellstrom, et al., "Antibodies for drug delivery," <i>Controlled Drug Delivery</i> , 2 nd Ed., Robinson, et al. (Eds.), 1987 , 623-653	
	11	Humphreys, D.P., et al., "Formation of dimeric fabs in <i>Escherichia coli</i> : effect of hinge size and isotype, presence of interchain disulphide bond, Fab' expression levels, tail piece sequences and growth conditions," <i>J. of Immunological Methods</i> , 1997 , <i>209</i> , 193-202	

EXAMINER

DATE CONSIDERED

© 2006 WW

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Docket No. CELL-0308/PA535-USw01	Application No. 10/562,769
		Applicant Sam Philip Heywood, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 27, 2006	Group Not Yet Assigned
		Confirmation No. 7843	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	12	Humphreys, D.P., et al., "A plasmid system for optimization of Fab' production in <i>Escherichia coli</i> : importance of balance of heavy chain and light chain synthesis," <i>Protein Expression and Purification</i> , 2002, 26, 309-320	
	13	Leach, S.J., et al., "The electrolytic reduction of proteins," <i>Div. Protein Chem.</i> , 1965, 4, 23-27	
	14	Leong, S.R., et al., "Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation," <i>Cytokine</i> , 2001, 16, 106-119	
	15	Lyons, A., et al., "Site-specific attachment to recombinant antibodies via introduced surface cysteine residues," <i>Protein Engineering</i> , 1990, 3, 703-708	
	16	Mountain, A., et al., "Engineering antibodies for therapy," <i>Biotechnol. Genet. Eng. Rev.</i> , 1992, 10, 1-142	
	17	Orlandi, R., et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <i>Proc. Natl. Acad. Sci. USA</i> , 1989, 86, 3833-3837	
	18	Riechmann, L., et al., "Reshaping human antibodies for therapy," <i>Nature</i> , 1988, 322, 323	
	19	Rodrigues, M.L., et al., "Engineering Fab' fragments for efficient F(ab) ₂ formation in <i>Escherichia coli</i> and for improved in vivo stability," <i>The Journal of Immunology</i> , 1993, 151, 6954-6961	
	20	Rüegg, U.T., et al., "Reduction cleavage of cysteine disulfides with tributylphosphine," <i>Methods in Enzymology</i> , 1977, 47, 111-126	
	21	Seitz, U., et al., "Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183," <i>Euro. J. Nuclear Medicine</i> , 1999, 26, 1265-1273	
	22	Singh, R., et al., "Reagents for rapid reduction of disulfide bonds," <i>Methods in Enzymology</i> , 1995, 251, 167-173	
	23	Thorpe, P.E., et al., "The preparation and cytotoxic properties of antibody-toxin conjugates," <i>Immunol. Rev.</i> , 1982, 62, 119-158	
	24	Verma, R., et al., "Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems," <i>J. of Immunological Methods</i> , 1998, 216, 165-181	
	25	Ward, E., et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , 1989, 341, 544-546	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified	Docket No. CELL-0308/PA535-USw01	Application No. 10/562,769
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant Sam Philip Heywood, et al.	
U.S. Department of Commerce Patent and Trademark Office	Filing Date June 27, 2006	Group Not Yet Assigned
	Confirmation No. 7843	

U. S. PATENT DOCUMENTS

EXAMINER _____ **DATE CONSIDERED** _____

Form PTO-1449 Modified		Docket No. CELL-0308/PA535-USw01	Application No. 10/562,769
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Sam Philip Heywood, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 27, 2006	Group Not Yet Assigned
		Confirmation No. 7843	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	33	WO 89/01476 A1	02/23/89	PCT		
	34	WO 90/09195 A1	08/23/90	PCT		
	35	WO 91/09967 A1	07/11/91	PCT		
	36	WO 92/02551 A1	02/20/92	PCT		
	37	WO 92/22583 A2	12/23/92	PCT		
	38	WO 93/06231 A1	04/01/93	PCT		
	39	WO 97/36932 A1	10/09/97	PCT		
	40	WO 98/25971 A1	06/18/98	PCT		
	41	WO 98/37200 A3	08/27/98	PCT		
	42	WO 99/15549 A3	04/01/99	PCT		
	43	WO 03/031581 A3	04/17/03	PCT		
	44	WO2004043492 A1	05/27/04	PCT		
	45	0 392 745 B1	11/02/94	EP		
	43	0 968 291 B1	01/28/04	EP		

EXAMINER	/David Blanchard/	DATE CONSIDERED	02/07/2008
-----------------	-------------------	------------------------	------------

© 2006 WW

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DB/